Biomarker

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use.It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use.

Biomarkers are increasingly the topic of partnering and collaboration deals in the life sciences sector.

Numerous deals have been announced in relation to identification of biomarkers, the impact of therapeutic intervention on their presence/absnece, and their use to create companion diagnostics which allow objective measurement of a particular disease state.

It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

In medicine, a biomarker can be a traceable substance that is introduced into an organism as a means to examine organ function or other aspects of health.

For example, rubidium chloride is used as a radioactive isotope to evaluate perfusion of heart muscle.

It can also be a substance whose detection indicates a particular disease state, for example, the presence of an antibody may indicate an infection.

More specifically, a biomarker indicates a change in expression or state of a protein that correlates with the risk or progression of a disease, or with the susceptibility of the disease to a given treatment.

Biochemical biomarkers are often used in clinical trials, where they are derived from bodily fluids that are easily available to the early phase researchers.

A useful way of finding genetic causes for diseases such as schizophrenia has been the use of a special kind of biomarker called an endophenotype.

In cell biology, a biomarker is a molecule that allows for the detection and isolation of a particular cell type (for example, the protein Oct-4 is used as a biomarker to identify embryonic stem cells).

In genetics, a biomarker (identified as genetic marker) is a DNA sequence that causes disease or is associated with susceptibility to disease.

They can be used to create genetic maps of whatever organism is being studied.

Read: more on biomarker deals in pharma, biotech, life science partnering deal news, insights and glossary

Example biomarker deal from Current Agreements life sciences partnering, M&A and financing deals database:

Collaboration agreement for utrophin biomarkers

Summit, Children's National Medical Center

Feb 6, 2013

Summit has entered into a collaboration with Dr Yetrib Hathout from Children’s National Medical Center in Washington DC, for the development of utrophin biomarkers for DMD.

The collaboration is being financially supported by a grant from the Foundation to Eradicate Duchenne and is part of a comprehensive biomarker programme being undertaken by Summit to advance its utrophin modulator programme for DMD.

In late 2012, Summit reported that in a Phase 1 trial in healthy volunteers, its lead candidate SMT C1100 was safe and well-tolerated.

 

For more information about this and hundreds more biomarker deals:

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Report: Biomarker Partnering Terms and Agreements

Report: Personalized Medicine Partnering Terms and Agreements

Read: more on biomarker deals in pharma, biotech, life science partnering deal news, insights and glossary

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database - includes comprehensive coverage of all deals and alliances for the top 50 pharma companies – find out more

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Financing Scorecard – view top life science financing deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Print Friendly, PDF & Email